Concurrently, alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) continue to function as key serum biomarkers in the clinical evaluation and longitudinal monitoring of HCC [9,10], yet reliable biomarkers for predicting treatment response in systemic therapy remain undefined. The gene discussed is AFP; the disease is hepatocellular carcinoma.